ArticleEndocrine-related cancer2017
The microenvironment induces collective migration in
Article in Endocrine-related cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Similar deficiencies, different outcomes: succinate dehydrogenase loss in adrenal medulla vs. fibroblast cell culture models of paraganglioma.Cancer & metabolism · 2024Article
- Review
- Single-cell RNA-Seq reveals the heterogeneity of fibroblasts within the tympanojugular paraganglioma microenvironment.Heliyon · 2024Article
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- The 3D in vitro Adrenoid cell model recapitulates the complexity of the adrenal gland.Scientific reports · 2024Article
- Tumour microenvironment in pheochromocytoma and paraganglioma.Frontiers in endocrinology · 2023Review
- Sclerosing Paragangliomas: Correlations of Histological Features with Patients' Genotype and Vesicular Monoamine Transporter Expression.Head and neck pathology · 2022Article
- Metformin Treatment Induces Different Response in Pheochromocytoma/Paraganglioma Tumour Cells and in Primary Fibroblasts.Cancers · 2022Article
- Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS.International journal of molecular sciences · 2022Article
- Effects of metabolic cancer therapy on tumor microenvironment.Frontiers in oncology · 2022Review
- Three Dimensional Cell Culturing for Modeling Adrenal and Pituitary Tumors.Pathology oncology research : POR · 2021Article
- Pheochromocytoma/paraganglioma preclinical models: which to use and why?Endocrine connections · 2020Review
- A narrative review of the role of fibroblasts in the growth and development of neurogenic tumors.Annals of translational medicine · 2020Review
- Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma.International journal of molecular sciences · 2020Article
- The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia.International journal of molecular sciences · 2020Review
- Mitochondrial metabolism and cancer metastasis.Annals of translational medicine · 2020Review
- A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats.Endocrine-related cancer · 2020Article
- Germline Mutation inInternational journal of endocrinology · 2020Article
- Article
- Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells.Cell and tissue research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pheochromocytomas (Pheos) and paragangliomas (PGLs) are neuroendocrine tumors. Approximately 30-40% of Pheos/PGLs are due to germline mutations in one of the susceptibility genes, including those encoding the succinate dehydrogenase subunits A-D (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.